Loading...
XNASPCSA
Market cap2mUSD
Dec 24, Last price  
0.84USD
1D
0.37%
1Q
-36.82%
IPO
-96.00%
Name

Processa Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:PCSA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-24.46%
Rev. gr., 5y
%
Revenues
0k
140,00020,000192,145312,480200,201113,4255,0000000000
Net income
-11m
L-79.72%
-160,000-940,000-2,440,538-3,068,701-4,526,250-3,354,227-335,982-1,856,315-3,765,047-3,357,876-14,413,788-11,427,534-54,848,458-11,121,520
CFO
-8m
L-16.05%
-160,000-710,000-1,886,500-2,538,769-2,695,448-871,906-43,203-1,654,617-3,707,914-2,750,145-3,143,196-8,717,291-9,605,143-8,063,346
Earnings
Mar 27, 2025

Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
URL
https://www.processapharmaceuticals.com/
IPO date
Oct 07, 2013
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
11,457
47,783
23,701
Unusual Expense (Income)
NOPBT
(11,457)
(47,783)
(23,701)
NOPBT Margin
Operating Taxes
27,424
(531)
Tax Rate
NOPAT
(11,457)
(75,207)
(23,170)
Net income
(11,122)
-79.72%
(54,848)
379.97%
(11,428)
-20.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,321
(389)
9,985
BB yield
-1,440.46%
2.19%
-13.30%
Debt
Debt current
167
79
71
Long-term debt
217
380
86
Deferred revenue
Other long-term liabilities
(2,146)
Net debt
(4,321)
(6,045)
(14,195)
Cash flow
Cash from operating activities
(8,063)
(9,605)
(8,717)
CAPEX
(3)
Cash from investing activities
(3)
Cash from financing activities
6,269
(389)
9,799
FCF
(10,778)
(75,394)
(24,015)
Balance
Cash
4,706
6,504
16,498
Long term investments
(2,146)
Excess cash
4,706
6,504
14,352
Stockholders' equity
(75,369)
(64,246)
(36,822)
Invested Capital
80,592
71,946
60,240
ROIC
ROCE
EV
Common stock shares outstanding
1,312
16,109
15,319
Price
0.33
-69.58%
1.10
-77.55%
4.90
-25.64%
Market cap
439
-97.52%
17,720
-76.39%
75,065
51.88%
EV
(3,883)
11,676
60,870
EBITDA
(11,457)
(46,994)
(22,910)
EV/EBITDA
0.34
Interest
101
362
Interest/NOPBT